|
(Health-NewsWire.Net, November 20, 2019 ) Market Overview
Mantle cell lymphoma (MCL) is a rare type of blood cancer, which occur due to the excessive growth of lymphocytes. Mantle cell lymphoma (MCL) is one of the B-cell Non-Hodgkin lymphomas, which occur as a result of the formation of tumours in the lymph nodes, which enters the blood and spreads to the bone marrow, spleen, digestive tract, and liver.
Market Dynamics
The major driving forces are the growing prevalence of mantle cell lymphoma, increasing research & development activities in the healthcare sector resulting in a robust product pipeline.
The rising prevalence of mantle cell lymphoma is expected to propel market growth over the forecast period. For instance, according to a study by Drug Development Technology, 2017, an estimated 3,300 new cases of mantle cell lymphoma are diagnosed each year in the US. It is estimated that in 2017, there were approximately 14,030 incident cases of mantle cell lymphoma globally, and forecasts that number to increase to 18,010 incident cases by 2026. It is also estimated that the majority of diagnosed cases were male in 2017. The incidence of MCL is highest among older individuals aged 60+ years. Thus, the rising prevalence of mantle cell lymphoma is driving the market.
The presence of an increasing number of research and development activities is expected to drive the market. For instance, as per the article published on October 9, 2019, according to Simon Rule, looking forward to the further therapeutic approaches in the frontline setting of Mantle Cell Lymphoma (MCL), he explained that the BTK inhibitors could take over the upfront space and potentially in combination, and chemotherapy will be a subsequent action. Further, according to an article published on May 9, 2019, a study by the University of Texas, and MD Anderson Cancer Center demonstrated that a small molecule drug, named IACS-10759 might help overcome ibrutinib resistance in mantle cell lymphoma.
The promising mantle cell lymphoma pipeline is expected to drive market growth over the forecast period. For instance,
Company/University Study title Phase Anticipated launch
AstraZeneca A prospective disease registry of the patients with mantle cell lymphoma treated with novel agents Not applicable March 20, 2024
Seoul National University Hospital A Phase 2 trial to assess the efficacy of bortezomib, cytarabine, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma Phase 2 June 2025
PrECOG, LLC. In collaboration with Takeda A Phase I/II study of ixazomib and ibrutinib in relapsed/refractory mantle cell lymphoma Phase 1/2 December 2024
Kosin University Gospel Hospital in collaboration with Takeda Multicenter Phase II study of ixazomib maintenance in patients with newly diagnosed mantle cell lymphoma Phase 2 December 2022
However, serious side effects of drugs like anaemia, neutropenia, and diarrhoea are the factors restraining market growth.
Download Free Sample: https://www.datamintelligence.com/download-sample/mantle-cell-lymphoma-market
Market Segmentation
By therapy type, the mantle cell lymphoma market can be segmented into chemotherapy, targeted therapy, radiotherapy, and others.
The targeted therapy segment is expected to grow at a high rate over the forecast period. The development of the targeted agents with low toxicity profiles for the treatment of relapsed mantle cell lymphoma (MCL) in combination with approved drugs is a major factor augmenting the mantle cell lymphoma treatment market growth. According to an article published on October 14, 2019, the introduction of the novel targeted agents ibrutinib (Imbruvica), acalabrutinib (Calquence), and venetoclax (Venclexta), among others, is rapidly changing the relapsed/refractory space of mantle cell lymphoma (MCL) and the upfront setting of chronic lymphocytic leukaemia (CLL), according to James N. Gerson, MD.
For instance,
Company/University Study title Phase Anticipated launch
PrECOG, LLC. In collaboration with Genentech, Inc. Phase II study of bendamustine and rituximab plus venetoclax in untreated mantle cell lymphoma over 60 years of age Phase 2 March 2025
Washington University School of Medicine in collaboration with Acerta Pharma BV A Pilot Study of acalabrutinib with bendamustine/rituximab followed by cytarabine/rituximab for untreated mantle cell lymphoma Phase 2 November 2025
Enquire Before Purchase: https://www.datamintelligence.com/enquiry/mantle-cell-lymphoma-market
Geographical Analysis
Geographically, the global mantle cell lymphoma market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America is dominating the global mantle cell lymphoma market in 2018 and is estimated to hold significant market size over the forecast period (2019-2026) owing to the increasing incidence of mantle cell lymphoma, and the presence of an increasing number of research and development activities.
The increasing incidence of mantle cell lymphoma is expected to grow at a high rate over the forecast period. For instance, according to the Leukemia and Lymphoma Society, about 70,800 new cases of non-Hodkin Lymphoma were registered in the US, where mantle cell lymphoma represented about 6% or 4,200 cases of the total cases. Also, according to a study published in Cancer Journal for Clinicians stated that 3,320 new cases of MCL were diagnosed in the US in 2016.
Also, the FDA's Center for Drug Evaluation and Research Agency works with the manufacturers to analyze drug development, drug approval, promising the breakthrough therapy destination Program to make treatments available for patients with a rare disease. For instance, the FDA approved Imbruvica (ibrutinib), manufactured by Janssen Pharmaceuticals, Inc. is a breakthrough therapy designation to treat patients with mantle cell lymphoma, a rare and aggressive type of blood cancer.
The presence of an increasing number of research and development activities in the region is expected to drive the market.
For instance,
University Study title Phase Anticipated launch
M.D. Anderson Cancer Center in collaboration with the National Cancer Institute A Phase 2 study of ibrutinib plus rituximab followed by venetoclax and Hyper-CVAD consolidation in the newly diagnosed young patients with MCL: window II protocol Phase 2 May 2021
University of Michigan Rogel Cancer Center Phase I multi-site study evaluating the MTD, safety and efficacy of the combination venetoclax, lenalidomide and rituximab in the patients with previously untreated mantle cell lymphoma Phase 1 July 2022
Competitive Landscape
The major players operating in the global mantle cell lymphoma market are F. Hoffman La Roche Ltd, Abbvie, Inc., Kite Pharma, Inc. (Gilead Sciences, Inc.), Celgene Corporation, Eli Lilly and Company, Amgen, Inc., Takeda Pharmaceutical Co. Ltd, AstraZeneca Plc, and Johnson and Johnson.
The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the mantle cell lymphoma market globally. For instance,
On November 6, 2019, Eli Lilly and Company announced that multiple abstracts from the LOXO-305 program had been accepted for the presentation at the 61st American Society of Hematology Annual Meeting and Exposition to be held in December 7-10, 2019 in Orlando, Florida. LOXO-305 is a next-generation, highly selective, non-covalent BTK inhibitor.
On May 28, 2019, Celgene Corporation announced that the US FDA had approved REVLIMID (lenalidomide) in combination with a rituximab product for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma (MZL) following Priority Review designation. REVLIMID is intended for the treatment of adult patients with MCL, whose disease has relapsed or progressed after 2 prior therapies, one of which included bortezomib.
On May 7, 2019, AstraZeneca announced positive results from the Phase 3 ASCEND trial of Calquence (Acalabrutinib) in previously-treated patients with CLL. Calquence was approved for the treatment of adults with relapsed/refractory MCL in the US, the UAE, Brazil, and Qatar, and is being developed for the treatment of CLL and other blood cancers.
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
|
